natgillin/translations-raw huggingface dataset:
meni, da mora biti namen politike EU, da se v državah v razvoju kar najbolj poveča razpoložljivost farmacevtskih izdelkov po dostopnih cenah; poziva Komisijo, naj upošteva možnost nakupa nekaterih patentov najpomembnejših zdravil ter jih da v javni sektor;
Believes that the EU policy should aim at maximising the availability of pharmaceutical products at affordable prices in the developing world; calls on the Commission to consider the possibility of buying some patents of essential medicines, and to put them in the public sector;
poziva Komisijo, naj javno podpre takojšnjo uporabo člena 30 sporazuma TRIPS v vseh državah, ki se soočajo z večjimi epidemijami in imajo težave pri dostopu do potrebnih zdravil; poziva Svet, naj skupaj s Parlamentom sprejme skupno politično izjavo, da države članice EU še naprej uporabljajo določbo člena 30 o izvzetju sporazuma TRIPS v njihovem domačem patentnem pravu za dovoljevanje proizvodnje in izvoza "z namenom reševanja potreb javnega zdravja in držav uvoznic" ter poziva Svet, naj Komisijo pooblasti, da se vzdrži sprejemanja ukrepov, ki bi posegali v te postopke;
Calls on the Commission to publicly support the immediate use of Article 30 of the TRIPS Agreement by all countries facing major epidemics and that experience difficulties in gaining access to the necessary medicines; calls on the Council to adopt a Joint Policy Statement with Parliament to the effect that EU Member States remain free to use the Article 30 exception provision of the TRIPS Agreement under their domestic patent laws to authorise production and export 'with a view to addressing public health needs in importing Members' and asks the Council to mandate the Commission to refrain from taking action to interfere with these proceedings;
poziva Svet, naj pojasni, da Komisija nima pooblastila za pogajanja v dvostranskih in regionalnih sporazumih z državami v razvoju o določbah sporazuma TRIPS-plus, ki so povezane s farmacevtskimi proizvodi in vplivajo na javno zdravje in dostop do zdravil;
Calls on the Council to make it clear that the Commission has no mandate to negotiate pharmaceutical-related TRIPS-plus provisions affecting public health and access to medicines, of bilateral and regional agreements with developing countries;
poziva Svet, naj Komisijo pooblasti, da se vzdrži od zahteve za zavezanost k obveznostim (ali njihov sprejem) Pogodbe o sodelovanju na področju patentov in Pogodbe o patentnem pravu, da se vzdrži vključitvi določb Direktive 2004/48/ES in da v sporazumu EPA ne bodo vključena pravila, kot na primer varstvo izvornih zbirk podatkov, in pogoji, ki bi z omejevanjem izbire držav AKP do sistema črpanja lahko zmanjšali področje uporabe vzporednega uvoza;
Calls on the Council to mandate the Commission to refrain from requesting adherence to or acceptance of the obligations of the Patent Cooperation treaty and the Patent Law Treaty, to refrain from incorporating the terms of Directive 2004/48/EC, not to introduce in the EPAs rules such as no original database protection, and not to include conditions which, by limiting ACP countries' choice of exhaustion regime, can reduce the scope of parallel imports;
meni, da mora EU namesto proaktivne uporabe vseh dvostranskih in regionalnih sporazumov zahtevati dodatne posebne določbe z ustvarjanjem okvira za učinkovito izvajanje sklepa iz avgusta 2003 ter za uporabo popolne prožnosti za sektor javnega zdravja v sporazumu TRIPS v skladu z deklaracijo iz Dohe;
Considers that the EU should instead proactively use all bilateral and regional agreements to require further specific provisions creating the framework for an effective implementation of the August 2003 Decision and for the use of the full flexibilities for public health under the TRIPS Agreement in compliance with the Doha Declaration;
poudarja, da so solidne javnozdravstvene storitve, vključno z raziskovalnimi zmogljivostmi, pomembne za boj proti epidemiji, ter nasprotuje pogojevanju, ki vodi do njihove liberalizacije;
Stresses that strong public health services, including research facilities, are essential in order to fight the epidemic, and opposes the situation of conditionality leading to their liberalisation;
poziva, naj se podpre razvoj regionalne in nacionalne proizvodnje generičnih zdravil na prizadetih območjih, zato da se omogoči dostop do dostopnih zdravil;
Calls for support for the development of regional and national generic pharmaceutical-producing industries in affected areas with a view to facilitating access to affordable drugs;
poziva Svet, naj prizna, da mora Evropska unija nujno sprejeti dodatne ukrepe, s katerimi se bodo spodbudili prenos tehnologije, raziskav, krepitev zmogljivosti, regijski oskrbovalni sistemi in pomoč pri registraciji, da bi olajšali in povečali proizvodnjo farmacevtskih izdelkov v državah v razvoju;
Calls on the Council to recognise that the European Union must take additional measures as a matter of urgency with a view to encouraging the transfer of technology, research, capacity strengthening, regional supply systems and help with registration, in order to facilitate and increase the production of pharmaceutical products by the developing countries themselves;
poziva Svet, naj se do določene ravni zaveže za financiranje za posodobitev ali izgradnjo zmogljivosti za proizvodnjo farmacevtskih proizvodov pri lokalnih lastnikih v državah v razvoju ter poveča skupno financiranje za javne raziskave in razvoj zdravil, ki so posebej pomembna za države v razvoju, ter za zagotavljanje, da bodo patenti iz teh raziskav ostali javni;
Asks the Council to commit to a specified level of funding to upgrade or construct pharmaceutical production facilities owned by local persons in developing countries and increase the EU aggregate funding to public research and development of medicines of special relevance to developing countries, and to guarantee that the patents resulting of such research remain public;
poziva Komisijo, naj omogoči financiranje za raziskave in razvoj bolezni, povezanih z revščino, tropskih bolezni in zapostavljenih bolezni za širok spekter krajev, za podporo raziskovalnim inštitutom, ki so pripravljeni sodelovati pri pobudah za javno zdravje, namenjene tem prizadevanjem, ter naj zagotovi, da se ugotovitve, kot rezultat raziskav o novih zdravilih, ki se financirajo z javnimi sredstvi, ne patentirajo, ampak ostanejo javne;
Asks the Commission to grant funding for R&D on poverty-related, tropical and neglected diseases across a broad spectrum of venues, to support research institutes willing to cooperate with public health initiatives dedicated to these efforts, and to guarantee that findings resulting of research on new medicines financed by public founding's will not be patented but will remain public;
poziva Komisijo, naj podpre razkritje (s strani prijaviteljev patentov) vira in izvora izumov, ki izhajajo iz bioloških virov in so povezani s tradicionalnim znanjem držav v razvoju, da bi se spodbujala pravična porazdelitev koristi in tehnologije iz teh držav;
Asks the Commission to support disclosure by patent applicants of the source and origin of inventions deriving from biological resources and associated traditional knowledge found in developing countries with a view to promoting the equitable sharing of benefits and technology derived from those resources by supplying countries;
poziva Komisijo, naj podpre 'strategije javnih naročil' iz člena 31(b) in druge strategije, ki bi jih lahko uporabljale države ali skupine držav za zagotavljanje večje kupne moči in ekonomije obsega pri proizvodnji generičnih zdravil po dostopnih cenah in pospeševanje neposrednih naložb v zmogljivosti lokalne proizvodnje v regiji;
Calls on the Commission to support 'pool procurement strategies' under Article 31(b) and other strategies which could be used by countries or groups of countries to provide greater buying power and economies of scale in the production of generic medicines at affordable prices and stimulate direct investment in local production facilities within a region;
poziva Svet in Komisijo, naj Komisijo pooblastita, da proaktivno podpre delo medvladne delovne skupine za javno zdravje, inovacije in postopek intelektualne lastnine (IGWG) pri WHO, kot so predlogi za ponovno preučitev povezave med oblikovanjem cen in stroški za raziskave in razvoj z namenom izpeljave novih modelov, ter da Parlamentu o svojem delu redno poroča; poziva tudi Svet, naj predvidi možnost, da bi Parlament v skupini IGWG uradno predstavljali nekateri njegovi člani;
Asks the Council to mandate the Commission to proactively support the work of the Intergovernmental Working Group on Public Health, Innovation and Intellectual Property (IGWG) at the WHO such as proposals that re-examine the link between pricing and the cost of R&D with a view to devising workable new models, and to report regularly to Parliament on its work; also asks the Council to envisage the possibility of having Parliament officially represented at the IGWG by some of its Members;
spodbuja farmacevtska podjetja, naj si prizadevajo za druge možnosti oblikovanja cen, ki bodo vključevala velik obseg, pristop nizke zgornje meje, s čimer se lahko poveča dostopnost zdravil;
Encourages pharmaceutical companies to pursue pricing alternatives involving a high-volume, low-margin approach, which could enhance access to medicines;
opozarja, da ponarejanje zdravil ni vprašanje patenta kot takega;
Recalls that counterfeiting of medicines is not a patent issue as such;
k vprašanju za ustni odgovor B6‑0277/2007
further to Question for Oral Answer B6‑0134/2007
ki ga vlagajo Miroslav Ouzký, Georgs Andrejevs in John Bowis
by Miroslav Ouzký, Georgs Andrejevs and John Bowis
o ukrepih za obravnavo bolezni srca in ožilja
on action to tackle cardiovascular disease
Resolucija Evropskega parlamenta o ukrepih za obravnavo bolezni srca in ožilja
European Parliament resolution on action to tackle cardiovascular disease
ob upoštevanju člena 152 Pogodbe o ES,
having regard to Article 152 of the EC Treaty,
ob upoštevanju sklepov seje Sveta za zaposlovanje, socialno politiko, zdravje in varstvo potrošnikov 1. in 2. junija 2004 http://www.consilium.europa.eu/ueDocs/cms_Data/docs/pressData/en/lsa/80729.pdf ,
having regard to the conclusions of the Employment, Social Policy, Health and Consumer Affairs Council meeting on 1-2 June 2004 http://www.consilium.europa.eu/ueDocs/cms_Data/docs/pressData/en/lsa/80729.pdf ,
ob upoštevanju predloga Komisije o vzpostavitvi drugega programa ukrepov Skupnosti na področju zdravja (2007–2013) KOM(2006) 234 konč. ,
having regard to the Commission Proposal for a Public Health Action Programme 2007-2013 COM(2006) 234 final ,
ob upoštevanju resolucije Evropskega parlamenta o zakonodajnem in delovnem programu Komisije za leto 2006, kjer je Komisijo pozval, naj zagotovi „ primerno nadaljnje spremljanje svojih sporočil o boju proti debelosti, boleznim srca, sladkorni bolezni, raku, duševnim motnjam in HIV/AIDS “ P6_TA(2005)0524 ,
having regard to the European Parliament’s Resolution on the Commission legislative and work programme for 2006, which called on the Commission to ‘ensure a proper follow-up to its communications on the fight against obesity, heart diseases, diabetes, cancer, mental disorders and HIV/AIDS’ P6_TA(2005)0524 ,
ob upoštevanju evropske strategije za preprečevanje in obvladovanje nenalezljivih bolezni EUR/RC56/R2 , ki jo je sprejela Svetovna zdravstvena organizacija,
having regard to the World Health Organisation’s ‘European Strategy for the Prevention and Control of Noncommunicable Diseases’ EUR/RC56/R2 ,
ob upoštevanju sklepov in strateških ciljev glede žensk in zdravja v pekinški deklaraciji in Izhodiščih za ukrepanje, sprejetih na četrti svetovni konferenci Združenih narodov o ženskah,
having regard to the conclusions and strategic objectives on women and health of the Beijing Declaration and Platform for Action, 4th UN World Conference on Women,
ob upoštevanju konference o zdravju srca, ki je potekala junija 2005 v Luxembourgu http://www.worldheartday.com/articulos/LuxembourgDeclaration.pdf ,
having regard to the June 2005 Luxembourg Heart Health Conference http://www.worldheartday.com/articulos/LuxembourgDeclaration.pdf ,
ob upoštevanju konference o zdravju srca pri ženskah marca 2006 http://www.cvhconference.org ,
having regard to the March 2006 Women’s Health at Heart Conference http://www.cvhconference.org ,
ob upoštevanju pobude finskega predsedstva o zdravju v vseh politikah http://www.stm.fi/Resource.phx/eng/subjt/inter/eu2006/hiap/index.htx.i1153.pdf ,
having regard to the Finnish Presidency’s Health in All Policies initiative http://www.stm.fi/Resource.phx/eng/subjt/inter/eu2006/hiap/index.htx.i1153.pdf ,
ob upoštevanju sedmega okvirnega programa za raziskave KOM(2006) 364 konč. ,
having regard to the Seventh Research Framework Programme COM (2006) 364 final ,
ker so glede na evropske statistične podatke o boleznih srca in ožilja za leto 2005 te bolezni najpogostejši vzrok smrti pri moških in ženskah v Evropski uniji, kar pomeni 1,9 milijona smrti; ker bolezni srca in ožilja moške in ženske prizadenejo različno; ker je pri ženskah večja verjetnost, da umrejo zaradi kapi ali srčnega napada kot pri moških; ker bolezni srca in ožilja pri ženskah pogosto niso diagnosticirane in ustrezno zdravljene Študija: Discrimination against Women and Young Girls in the Health Sector, Oddelek za tematsko področje C, PE 378.295 ,
whereas, according to the European cardiovascular disease statistics 2005, cardiovascular disease is the largest cause of death of men and women in the European Union, accounting for 1.9 million deaths ; whereas women and men are affected differently by cardiovascular disease; whereas women are more likely than men to die from stroke or heart attack; whereas cardiovascular diseases in women are often not diagnosed and treated properly Study: Discrimination against Women and Young Girls in the Health Sector, Policy Department C, PE 378.295 ,
ker bolezni srca in ožilja povzročijo skoraj polovico, 42 %, vseh smrti v EU Prav tam. ,
whereas cardiovascular disease causes nearly half of all deaths, 42%, in the EU Ibid. ,
ker so bolezni srca in ožilja drugi najpogostejši vzrok za breme bolezni (bolezen in smrt) v EU in predstavljajo 18 % bremena Prav tam. ,
whereas cardiovascular disease is the second main cause of disease burden (illness and death) in the EU, amounting to 18% of the burden Ibid. ,
ker celotni stroški bolezni srca in ožilja v EU znašajo 169 milijard EUR, pri čemer je 105 milijard EUR namenjenih za zdravljenje bolezni v EU, 64 milijard EUR pa nastane zaradi manjše storilnosti in stroškov neformalne nege Prav tam. ,
whereas the total cost of cardiovascular disease amounts to € 169 billion in the EU, of which € 105 billion is spent on treating the disease in the EU and € 64 billion is due to lost productivity and the cost of informal care Ibid. ,
ker je zdravje stanje popolnega telesnega, duševnega in socialnega blagostanja in ne le odsotnost bolezni ali invalidnosti,
whereas health is a state of complete physical, mental and social well-being and not merely the absence of disease or infirmity,
ker je zaradi spreminjajoče se demografske strukture EU potrebna daljša delovna doba ter ker oslabelost zaradi visokega krvnega pritiska in bolezni srca in ožilja negativno vplivajo na delovno silo High Blood Pressure and Health Policy, Kanavos/Őstergren/Weber et al., 2007. ,
whereas the changing demographic structure of the EU requires longer working lives and whereas debilitation from high blood pressure and cardiovascular diseases have a negative effect on the labour force High Blood Pressure and Health Policy, Kanavos/Őstergren/Weber et al., 2007. ,
ker je v indikatorjih OECD za leto 2005 Health at a Glance – kazalniki OECD za leto 2005.
whereas the OECD 2005 Indicators Health at a Glance – OECD Indicators 2005.
November 2005. navedeno, da se pri sedanjih izdatkih za zdravje le približno 3 % sredstev porabi za preventivne programe in programe na področju javnega zdravja,
November 2005. state that ‘ only around 3% of current health expenditure is spent on prevention and public health programmes’ ,
ker so glavni dejavniki za razvoj bolezni srca in ožilja uživanje tobaka in alkohola ter preveč trebušne maščobe, kar lahko povzroči presnovne motnje, visoke vrednosti glukoze, lipidov in holesterola v krvi ter visok krvni pritisk,
whereas major risk factors for developing a cardiovascular disease are notably consumption of tobacco and alcohol, an excess of visceral fat, which may lead to metabolic disorders, a high level of glucose, lipids and cholesterol in the blood and high blood pressure,
ker je mogoče večino bolezni srca in ožilja preprečiti s spremembo načina življenja ter zgodnjim odkrivanjem zelo ogroženih posameznikov in pravilno diagnozo,
whereas the majority of cardiovascular disease can be prevented by a change in lifestyle together with early identification of high-risk individuals and proper diagnosis,
ker Svetovna zdravstvena organizacija ugotavlja, da so stroškovno najbolj učinkovite metode za zmanjšanje ogroženosti celotne populacije ukrepi v vsej populaciji, ki združujejo učinkovito politiko in široko zastavljeno politiko za spodbujanje zdravja Sporočilo Svetovne zdravstvene organizacije – Bolezni srca in ožilja: preprečevanje in obvladovanje, WHO, 2003, dostopno na http://www.who.int/dietphysicalactivity/media/en/gsfs_cvd.pdf ,
whereas the WHO recognises that ‘the most cost-effective methods of reducing risk among an entire population are population-wide interventions, combining effective policies and broad health promotion policies’ WHO Information sheet - Cardiovascular diseases: prevention and control, WHO, 2003, available at http://www.who.int/dietphysicalactivity/media/en/gsfs_cvd.pdf ,
ker ni oprijemljive evropske strategije za obravnavo bolezni srca in ožilja,
whereas a tangible European strategy to address cardiovascular disease is non-existent,
ker je konferenca o zdravju srca pri ženskah v sklepih marca 2006 pozvala države članice, naj sprejmejo priporočilo o oprijemljivi strategiji EU za zdravje srca in ožilja na podlagi predloga Komisije, ki naj obsega spodbujanje zdravja srca in ožilja, mehanizme za podporo strategij in dejavnosti v državah članicah na področju srca in ožilja, smernice za oceno ogroženosti, najboljše preventivne metode, zdravljenje, rehabilitacijo in odkrivanje ter izobraževanje med zdravniki,
whereas the March 2006 Women’s Health at Heart conclusions called for the Member States to adopt an EU Recommendation on a tangible EU-wide cardiovascular health strategy on the basis of a Commission proposal encompassing cardiovascular health promotion, mechanisms in support of the Member States’ strategies and activities, guidelines on risk assessment, optimal preventive methods, treatment, rehabilitation and screening, and education of doctors by doctors,
ker so med državami članicami velike razlike v razširjenosti, preprečevanju in zdravljenju bolezni srca in ožilja, vloga EU pa je, da si prizadeva odpraviti neenakosti in odpraviti razlike,
whereas there are major discrepancies in cardiovascular disease prevalence, prevention and care between Member States and it is the role of the EU to combat such inequalities and close the gap,
ker je spol ključni dejavnik pri razvoju, diagnosticiranju, zdravljenju in preprečevanju bolezni srca in ožilja; ker se v zdravstvu spolu ne posveča dovolj pozornosti, kar škodljivo vpliva na zdravljenje bolezni srca in ožilja pri ženskah,
whereas gender is a crucial factor in the development, diagnosis, treatment and prevention of cardiovascular disease; whereas not enough attention is being paid to gender in the health sector, which is having a negative effect on the treatment of women for cardiovascular diseases,
ker so druge hude bolezni v Evropskem parlamentu v letu 2006 dobile veliko podporo s pisno izjavo o sladkorni bolezni P6_DCL(2006)0001 in predlogom resolucije o raku dojk v razširjeni Evropski uniji B6-0528/2006 , trenutno pa ni ničesar o boleznih srca in ožilja, ubijalcu številka 1 v Evropi,
whereas other major diseases received overwhelming support from the European Parliament in 2006 in the form of a Written Declaration on diabetes P6_DCL(2006)0001 and the Motion for a Resolution on breast cancer in the enlarged European Union B6-0528/2006 , while none currently exists on cardiovascular disease, the number 1 killer in Europe,
poziva Komisijo, naj predlaga priporočilo o boleznih srca in ožilja, vključno z visokim krvnim pritiskom, ter o zgodnjem odkrivanju zelo ogroženih posameznikov in preventivnih strategijah v Evropi, pri čemer se bodo upoštevale razlike med spoloma za zagotovitev enakosti spolov v zdravstvu;
Calls on the Commission to propose a Recommendation on cardiovascular disease including high blood pressure and on early identification of high-risk individuals and prevention strategies in Europe, taking into account gender differences so as to ensure gender equality in the health sector;
poziva države članice, naj razvijejo in okrepijo svoje sisteme za spremljanje dejavnikov tveganja;
Calls on Member States to develop and strengthen their risk factor surveillance systems;
poziva države članice, naj sprejmejo ali prenovijo nacionalne strategije za javno zdravje in vanje vključijo spodbujanje zdravja, populacijske strategije in strategije za zgodnje odkrivanje tveganja na področju zdravja srca in ožilja ter razvijejo ocenjevanje vpliva na zdravje, da bodo določile breme za nacionalne zdravstvene sisteme, upoštevajoč razlike med spoloma za zagotavljanje enakosti v zdravstvenem sektorju;
Calls on Member States to adopt or review national public health strategies to include health promotion, population and early high risk management strategies on cardiovascular health, and develop health impact assessments to measure the burden on national healthcare systems, taking into account gender differences so as to ensure gender equality in the health sector;
poziva države članice, naj oblikujejo smernice za preprečevanje bolezni srca in ožilja, skupaj z enotnimi smernicami najboljše prakse za zgodnje odkrivanje zelo ogroženih posameznikov;
Calls on Member States to establish national guidelines for the prevention of cardiovascular disease, including standard guidelines for best practice to identify high-risk individuals;
poziva Komisijo in države članice, naj se dogovorijo o določitvi ciljev za ureditev odkrivanja in spremljanja visokega krvnega pritiska;
Calls on the Commission and the Member States to establish a consensus in setting targets for managing high blood pressure screening and control;
spodbuja države članice, naj oblikujejo in izvajajo strategije za spodbujanje zdravja srca in ožilja, zgodnje odkrivanje zelo ogroženih skupin in preventivne strategije, saj so to stroškovno najučinkovitejše metode v boju proti boleznim srca in ožilja;
Encourages Member States to develop and implement cardiovascular health promotion, early identification of high-risk groups and prevention strategies, as the most cost-effective methods of combating cardiovascular disease;
poziva države članice, naj za spodbujanje zdravja srca in ožilja in preventivne strategije sprejmejo večsektorski pristop ob posvetovanju z vsemi zainteresiranimi stranmi;
Urges Member States to adopt a multisectoral approach to cardiovascular health promotion and preventive strategies in consultation with all relevant stakeholders;
poziva države članice, naj še naprej razvijajo akcijske načrte o dejavnikih zdravja, povezanih z načinom življenja, za spodbujanje zdravega načina življenja;
Calls on Member States to further develop their action plans on lifestyle-related health determinants to promote healthy lifestyles;
poziva k stalni finančni podpori na lokalni, nacionalni in evropski ravni za nadaljnje raziskave na področju preprečevanja bolezni srca in ožilja ter spodbujanja zdravja srca in ožilja, vključno z raziskavami o dejavnikih tveganja za bolezni srca in ožilja, razširjenosti in genetskih dejavnikih;
Calls for continued financial support for further research into preventing cardiovascular disease and promoting cardiovascular health at local, national and European level, including research on cardiovascular disease risk factors, prevalence and genetic factors;